Psychiatric symptoms of Parkinson's disease--an overview from the studies on dopaminergic nerves
Ishida, Y.
Seishin Shinkeigaku Zasshi 107(3): 290-293
2005
ISSN/ISBN: 0033-2658 PMID: 15856754 Document Number: 592772
Document emailed within 1 workday
Related Documents
Melamed, E.; Hefti, F.; Wurtman, R.J. 1982: Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model Israel Journal of Medical Sciences 18(1): 159-163Korczyn, A.D. 2003: Dopaminergic drugs in development for Parkinson's disease Advances in Neurology 91: 267-271
Zabek, M.; Mazurowski, W.; Dymecki, J.; Stelmachów, J.; Gawur, B.; Trautsolt, W.; Zawada, E. 1992: Transplantation of fetal dopaminergic cells in Parkinson disease Neurologia i Neurochirurgia Polska Suppl 1: 13-19
Agnoli, A.; Stocchi, F.; Carta, A.; Antonini, A.; Bragoni, M.; Ruggieri, S.A. 1988: Continuous dopaminergic stimulation in the management of complicated Parkinson's disease Mount Sinai Journal of Medicine new York 55(1): 62-66
Duvoisin, R.C. 1989: New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation Neurology 39(11 Suppl 2: 4-6
1997: Therapy of Parkinson disease. Continuous physiologic dopaminergic stimulation with carbergoline Der Nervenarzt 68(3 Suppl Therapie D): 1-4
Prabhakar, S.; Syal, P.; Srivastava, T. 2000: P300 in newly diagnosed non-dementing Parkinson's disease: effect of dopaminergic drugs Neurology India 48(3): 239-242
Clough, C.G.; Bergmann, K.J.; Yahr, M.D. 1984: Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration Advances in Neurology 40: 131-140
Hirsch, E.C. 2000: Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment Annals of Neurology 47(4 Suppl 1): S115
Bertrand, E.; Lechowicz, W.; Szpak, G.M.; Dymecki, J. 1997: Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease Neurologia i Neurochirurgia Polska 31(2): 295-302
Pokhabov, D.V.; Rudnev, V.A.; Prokopenko, S.V. 2003: The experience of dopaminergic agent decreased dosage with rhythmic pace gait correction in Parkinson disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 103(8): 76-77
Zheng, L.; Wang, H.; Ba, Y.-Y.; Liu, H.-L.; Wang, M.; Guo, W.-W.; Wu, X.; Yang, H. 2014: Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease Zhongguo Zhong Yao Za Zhi 39(9): 1660-1665
Henrichsmann, M. 2016: Psychotic symptoms in Parkinson's disease Medizinische Monatsschrift für Pharmazeuten 39(7): 293-295
Jansen, E.N.; Meerwaldtt, J.D. 1990: Madopar HBS in nocturnal symptoms of Parkinson's disease Advances in Neurology 53: 527-531
Santos-Garcia, D.; de Deus, T.; Tejera-Perez, C.; Exposito-Ruiz, I.; Suarez-Castro, E.; Carpintero, P.; Macias-Arribi, M. 2015: Gastroparesis and other gastrointestinal symptoms in Parkinson's disease Revista de Neurologia 61(6): 261-270
Santens, P.; Boon, P.; Van Roost, D.; Caemaert, J. 2003: The pathophysiology of motor symptoms in Parkinson's disease Acta Neurologica Belgica 103(3): 129-134
Kashihara, K. 2017: Neuropsychiatric symptoms in patients with Parkinson's disease Nihon Rinsho. Japanese Journal of Clinical Medicine 75(1): 105-110
Adam, Z.; Pour, L.; Krejcí, M.; Neubauer, J.; Vanícek, J.; Vasků, V.; Hájek, R. 2008: Langerhans cell histiocytosis in adult patients--a disease with many faces. Experience of a centre and an overview of the disease symptoms Vnitrni Lekarstvi 54(11): 1063-1080
Factor, S.A.; Molho, E.S.; Podskalny, G.D.; Brown, D. 1995: Parkinson's disease: drug-induced psychiatric states Advances in Neurology 65: 115-138
Sarycheva, T.N.; Rybak, V.A.; Kurushina, O.V. 2011: Ladasten in the management of non-motor symptoms of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 111(1): 85-87